Biodesix, Inc. BDSX

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertiseLOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tum

Biodesix has seen its fair value estimate move from US$30.83 to US$34.00, which works out to roughly a 10% uplift in the price target range used by analysts. Recent research coverage links this shift to a mix of optimism around revenue momentum and margin potential, along with some caution about execution and the timing of profitability. As you read on, you will see how these moving parts shape the current analyst narrative and what to watch as it evolves from here. Stay updated as the Fair...

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodulesLOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that Brianna Phillips, Vice President of Quality and Regulatory Affairs at Biodesix, will be presenting at the upcoming Regulatory Affairs Professionals Society (RAPS) and Society of Clinical Research Asso

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences: Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference1x1 meetings onlyDate: Thursday, September 10Location: New York, NY H.C. Wainwright 28th Annual Global Investment Conference1x1 meetings onlyDate: Tuesday, September 15Location: New Y

Moby summary of Biodesix, Inc.'s Q2 2026 earnings call